Facebook
Twitter
LinkedIn
Forward
Meeting the Challenges in Management of Sickle Cell Disease
No longer a life-threatening disease, sickle cell disease (SCD) has become a chronic disease with life-threatening events that requires coordinated care by a multidisciplinary care team. Join Michael DeBaun, MD, MPH, and Collin Montgomery, APRN, as they discuss the acute and chronic complications experienced by individuals with SCD and the barriers they often encounter. The faculty offer real-world strategies for overcoming these barriers to improve the quality of life and other health outcomes of patients with SCD. Learn about 4 medications approved for treating acute and chronic complications of SCD and how to optimize their use. Case studies are utilized to share the faculty’s experience and to facilitate integration into clinical practice.
Target Audience
This activity was developed for pediatric and adult hematologists, hematology nurse practitioners, emergency physicians, primary care physicians, pediatricians and other clinicians involved in the management of patients with sickle cell disease.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the causes and consequences of increased morbidity and mortality associated with sickle cell disease (SCD)
- Integrate key SCD management guideline recommendations into practice
- Compare and contrast standard, new, and emerging therapies for SCD—including mechanisms of action, dosing, safety and efficacy
- Employ communication and education strategies to help patients establish goals to improve their quality of life, prevent disease worsening, and have fewer/less severe symptoms
Additional Information
Michael R. DeBaun, MD, MPH
Professor of Pediatrics and Medicine
Vice Chair for Clinical and Translational Research
J.C. Peterson Chair in Pediatric Pulmonology
Director, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease
Vanderbilt Children’s Hospital
Nashville, Tennessee
Michael R. DeBaun, MD, MPH, discloses the following:
Advisory Board: Global Blood Therapeutics – clinical area: randomized controlled trial
Steering Committee: Novartis – clinical area: priapism
Collin Montgomery, APRN
APRN Coordinator, UAMS Adult Sickle Cell Program
University of Arkansas for Medical Sciences
Division of Hematology and Oncology
Department of Internal Medicine
UAMS Medical Center
Little Rock, Arkansas
Collin Montgomery, APRN, has no relevant financial relationships to disclose.
Provided by the Annenberg Center for Health Sciences at Eisenhower
AMA PRA Category 1 CreditsTM
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP Contact Hours
Accreditation Statement
Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
Designation Statement
This program is accredited for 1.25 contact hours. Program ID #5901-EM
Available Credit
- 1.25 AMA PRA Category 1 Credit™
This course is offered through MyCME.
To take this course you will be redirected to MyCME's website. You must login or create an account with MyCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!